Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Amicus Brief
May 21, 2018
| Rachel Schwartz
SAINT REGIS MOHAWK TRIBE and ALLERGAN, INC. v. MYLAN PHARMACEUTICALS, INC ., TEVA PHARMACEUTICALS USA, INC., and AKORN, INC.
Press Release
May 18, 2018
| Jeff Francer
AAM Files Brief to Oppose Pharmaceutical Company Abuse of the Patent System
Press Release
May 17, 2018
| Rachel Schwartz
Transparency an Important Step in Ending the Shenanigans
Press Release
May 16, 2018
| Rachel Schwartz
AAM Announces Additional 2018 Associate Members
Press Release
May 14, 2018
| Rachel Schwartz
AAM’s Comments on USTR’s Proposed China Tariffs
Blog
May 14, 2018
| Jeff Francer
AAM’s Comments on USTR’s Proposed China Tariffs
Press Release
May 14, 2018
| Rachel Schwartz
Tara Ryan Joins AAM as Vice President, State Government Affairs
Blog
May 14, 2018
| Jennifer Soup
Reinventing AAM’s Meetings
Press Release
May 11, 2018
| Rachel Schwartz
Generic and Biosimilar Competition Is Cornerstone of President Trump’s Blueprint to Lower Drug Prices for American Patients
Video
May 11, 2018
| Erica Klinger
AAM Responds to President Trump's Speech on Lowering Prescription Drug Prices
Blog
May 10, 2018
| David Gaugh
FDA Approvals: Good News for Patients, More Work to Do (Part 2)
Blog
May 10, 2018
| Chip Davis
Dear Mr. President—On the Eve of Your Drug-Pricing Speech
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2024
GRx+Biosims 2023
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action